279 related articles for article (PubMed ID: 11901096)
1. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
2. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
3. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Acheampong AA; Shackleton M; Tang-Liu DD
Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
[TBL] [Abstract][Full Text] [Related]
4. Non-systemic delivery of topical brimonidine to the brain: a neuro-ocular tissue distribution study.
Abdulrazik M; Tamilvanan S; Benita S
J Drug Target; 2006 Dec; 14(10):670-9. PubMed ID: 17162736
[TBL] [Abstract][Full Text] [Related]
5. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
6. Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Ophthalmol Ther; 2019 Jun; 8(2):271-277. PubMed ID: 30891685
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
8. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
9. A rapid and sensitive LC/MS/MS assay for the quantitation of brimonidine in ocular fluids and tissues.
Jiang S; Chappa AK; Proksch JW
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jan; 877(3):107-14. PubMed ID: 19109079
[TBL] [Abstract][Full Text] [Related]
10. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
11. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
Tajika T; Isowaki A; Sakaki H
J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
[TBL] [Abstract][Full Text] [Related]
12. Vitreous concentration of topically applied brimonidine tartrate 0.2%.
Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D
Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498
[TBL] [Abstract][Full Text] [Related]
13. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
[TBL] [Abstract][Full Text] [Related]
14. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.
Kadam RS; Jadhav G; Ogidigben M; Kompella UB
Drug Metab Dispos; 2011 Sep; 39(9):1529-37. PubMed ID: 21673129
[TBL] [Abstract][Full Text] [Related]
15. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
[TBL] [Abstract][Full Text] [Related]
16. Vitreous concentration of topically applied brimonidine-purite 0.15%.
Kent AR; King L; Bartholomew LR
J Ocul Pharmacol Ther; 2006 Aug; 22(4):242-6. PubMed ID: 16910864
[TBL] [Abstract][Full Text] [Related]
17. Ocular and systemic pharmacokinetics of brimonidine and brinzolamide after topical administration in rabbits: comparison between fixed-combination and single-drug formulations.
Suzuki G; Kunikane E; Shigemi W; Shinno K; Kozai S; Kurata M; Kawamura A
Curr Eye Res; 2021 Mar; 46(3):380-386. PubMed ID: 32706598
[TBL] [Abstract][Full Text] [Related]
18. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits.
Acheampong AA; Breau A; Shackleton M; Luo W; Lam S; Tang-Liu DD
J Ocul Pharmacol Ther; 1995; 11(4):489-502. PubMed ID: 8574812
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
Sjöquist B; Johansson A; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):240-9. PubMed ID: 10219468
[TBL] [Abstract][Full Text] [Related]
20. Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation.
Ishii K; Matsuo H; Fukaya Y; Tanaka S; Sakaki H; Waki M; Araie M
Invest Ophthalmol Vis Sci; 2003 Mar; 44(3):1169-77. PubMed ID: 12601046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
